Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) FCF Margin (2020 - 2025)

Historic FCF Margin for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to 8.71%.

  • Cytek Biosciences' FCF Margin fell 324200.0% to 8.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.0%, marking a year-over-year decrease of 172900.0%. This contributed to the annual value of 10.9% for FY2024, which is 105700.0% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' FCF Margin is 8.71%, which was down 324200.0% from 3.22% recorded in Q2 2025.
  • Cytek Biosciences' FCF Margin's 5-year high stood at 23.71% during Q3 2024, with a 5-year trough of 26.81% in Q2 2022.
  • Moreover, its 5-year median value for FCF Margin was 0.7% (2022), whereas its average is 1.37%.
  • As far as peak fluctuations go, Cytek Biosciences' FCF Margin skyrocketed by 353100bps in 2024, and later tumbled by -324200bps in 2025.
  • Quarter analysis of 5 years shows Cytek Biosciences' FCF Margin stood at 10.68% in 2021, then crashed by -107bps to 0.7% in 2022, then surged by 2073bps to 13.76% in 2023, then plummeted by -86bps to 1.92% in 2024, then crashed by -554bps to 8.71% in 2025.
  • Its FCF Margin stands at 8.71% for Q3 2025, versus 3.22% for Q2 2025 and 2.35% for Q1 2025.